Press releaseGlobe Newswire
Allarity Therapeutics
ALLR · NASDAQ
$0.8758+$0.0028 (+0.32%)TodayMarket closed ·
Prev close $0.873
Latest news
- Press releaseGlobe Newswire
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
- NewsAvi Kapoor
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
- Press releaseGlobe Newswire
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
- Press releaseGlobe Newswire
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
- Press releaseGlobe Newswire
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
- Press releaseGlobe Newswire
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
- Press releaseGlobe Newswire
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
- Press releaseGlobe Newswire
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
- Press releaseGlobe Newswire
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
- Press releaseGlobe Newswire
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Crude Oil Down 2%; US Durable Goods Orders Decline In July
- NewsAvi Kapoor
US Stocks Mixed; American Woodmark Posts Downbeat Sales
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsRishabh Mishra
Stock Market Today: Nasdaq 100 Futures Slip— Palo Alto, XP, Allarity Earnings In Focus (UPDATED)
- NewsAvi Kapoor
Palo Alto Networks, Fabrinet And 3 Stocks To Watch Heading Into Monday
- Press releasePRNewswire
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
- NewsRishabh Mishra
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert
- NewsAvi Kapoor
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday
- Press releaseGlobe Newswire
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
- Press releasePRNewswire
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
- Press releaseBusiness Wire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releaseBusiness Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
- Press releasePRNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR
- Press releaseBusiness Wire
ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
- Press releaseBusiness Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
- Press releasePRNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
- Press releasePRNewswire
ALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit
- Press releasePRNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit
- Press releaseGlobe Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
- Press releaseGlobe Newswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
- Press releasePRNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releasePRNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR
- Press releaseGlobe Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Allarity Therapeutics to Contact Us to Have Their Losses Evaluated Today
- Press releasePRNewswire
ALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit
- Press releasePRNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit
- Press releaseGlobe Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
- Press releaseGlobe Newswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
- Press releasePRNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releasePRNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.